Furthermore, the occurrence of EMT in NSCLC was detrimental to the enrichment of immunocompetent cells and would increase the release of immunosuppressive cytokines, such as TGF‐β60 to develop resistance to erlotinib target therapy through the TGFβ‐IL‐6 axis.61 This evidence concerns the gene IL6 and non-small cell lung carcinoma.